Aaron Waxman
Director of the Pulmonary Vascular Disease Program · Brigham and Women’s Hospital
Credentials: · · · · · ·
History
- Present
- 1997–1998
- 1992–1995
Internal Medicine
- 1988–1992
- 1991–1992
Research
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
New England Journal of Medicine · 2023 · 607 citations
Interleukin-6 overexpression induces pulmonary hypertension
Circulation Research · 2009 · Last of 6 authors · 536 citations
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
New England Journal of Medicine · 2021 · First of 16 authors · 514 citations
- DS
48 papers
20 papers
- JL
20 papers
19 papers
- MG
17 papers
- FR
16 papers · 2 as a fellow
15 papers
- SN
15 papers
Grants
- 2014–2021
Intergrated Endothelial Phenotyping to Redefine Pulmonary Hypertension
National Heart, Lung, and Blood Institute · U01
PI · $1.7M · Brigham and Women's Hospital
- 2004–2008
Il-6 Type Cytokine Protection from Hyperoxic Lung Injury
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.7M · Massachusetts General Hospital
- 1998–2004
Interleukin 11 Protection Hyperoxia Induced Lung Injury
National Heart, Lung, and Blood Institute · K08
Contact PI · $576.9K · Massachusetts General Hospital
Clinical trials
- 2025–2029
Open Label Treprostinil Raynaud's Study
Principal investigator · Recruiting · Phase 4
Brigham and Women's Hospital
- 2021–2024
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
Principal investigator · Completed · Phase 4
Brigham and Women's Hospital
- 2020–2023
A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
Principal investigator · Unknown · Phase 1
Gmax Biopharm LLC.
- 2018–2020
Angiogenic Imaging in Pulmonary Arterial Hypertension
Principal investigator · Completed · Phase 1, Phase 2
Brigham and Women's Hospital